Drugs / RN5681
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07347678 | Mar 2026 → Feb 2027 expected | — | Ikaria Bioscience Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Shanghai Rona Therapeutics Co., Ltd. | Regulatory Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction ronatherapeutics.com ↗
Shanghai, China; California, US — December 17, 2025 — Rona Therapeutics , a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company’s first bi-valent siRNA into clinical development. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Shanghai Rona Therapeutics Co., Ltd. | Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction ronatherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN5681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07347678 ↗ |
| Route | Subcutaneous | “Drug: RN5681 Investigational product subcutaneous injections” NCT07347678 ↗ |